NEW YORK, July 6, 2026, 15:09 (EDT)
- Recursion Pharmaceuticals, Inc. NASDAQ:RXRX was up 4.7% to $3.98 in afternoon trading, with volume at 26.7 million shares.
- The stock saw volume run over 19% ahead of its 22.42 million average, with trading not yet closed.
- Short interest was 184.02 million shares, or 36.8% of the float, so crowding risk remains high.
- Forecasts are spread, with Fintel showing a low target of $3.03 and MarketBeat at the high end with $11.00.
Nasdaq traded normally at the dateline after being shut July 3 for the Independence Day holiday. Recursion Pharmaceuticals, Inc. NASDAQ:RXRX rose 4.7% to $3.98 in the latest quote, adding about $95 million in market cap at that price.
The stock traded between $4.09 and $3.66. Volume reached 26.7 million shares, topping the 22.42 million average listed on Google Finance.
No same-day release from the company was driving the tape. The most recent item on Recursion’s press-release page was still dated June 2. The last full financial update posted was May 6.
RXRX traded against the grain of typical biotech and risk names:
| Instrument | Google Finance ticker format | Latest move | Latest price |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | NASDAQ:RXRX | rose 4.7% | $3.98 |
| SPDR S&P Biotech ETF | NYSEARCA:XBI | inched up 0.2% | $160.81 |
| iShares Nasdaq Biotechnology ETF | NASDAQ:IBB | edged down 0.1% | $195.58 |
| iShares Russell 2000 ETF | NYSEARCA:IWM | added 0.6% | $299.40 |
| Invesco QQQ Trust | NASDAQ:QQQ | was up 1.5% | $723.42 |
| SPDR S&P 500 ETF Trust | NYSEARCA:SPY | gained 0.9% | $751.77 |
Short interest keeps coming up for investors. Benzinga’s latest table puts RXRX’s shares short at 184.02 million, or 36.8% of float, with 8.36 days to cover. On Monday, volume covered just 14.5% of that short position, leaving most of the overhang.
This doesn’t prove short covering. It means the stock might swing hard before investors hear new clinical results.
Index moves added new pressure. MarketScreener, quoting S&P Capital IQ, said Recursion was added to the Russell 3000 Value Benchmark as of June 28. FTSE Russell said its June reconstitution changes kicked in after the U.S. market closed June 26, affecting about $12.2 trillion in assets tied to Russell U.S. indexes.
Jefferies NYSE:JEF equity analyst Steven DeSanctis told Reuters the June rebalance might trigger a “really massive trade.” Melissa Roberts at Stephens described that Friday as a “key liquidity day.” Reuters
Recursion wrapped Q1 with $665.2 million in cash, cash equivalents and restricted cash. The company posted a net loss of $117.5 million for the quarter. Recursion kept its 2026 cash-burn outlook below $390 million and said that leaves enough runway into early 2028 without more financing.
Chief Executive Najat Khan said progress with REC-1245 and REC-4539 offered “a growing set of proof points,” adding that the platform can turn “biological and chemical insights into differentiated clinical programs.” Recursion Pharmaceuticals, Inc.
Forecasts point to why it’s tough to value the stock based on just a single day’s trading:
| Forecast set | Rating / coverage | 12-month target data | Investor read |
|---|---|---|---|
| MarketBeat | Hold, based on 5 analysts: 1 sell, 2 hold, 2 buy | Targets average $8.10. Lowest is $5.50, high end $11.00 | MarketBeat is showing 103.26% upside from the $3.99 close |
| Fintel | Latest monthly forecast table | Estimates: average $6.20, median $5.86, low $3.03, high $10.50 | Forecasts span below current market up to 160% above RXRX price |
| MarketScreener / FactSet | Outperform, 8 analysts in coverage | Consensus target at $6.643 | This source puts upside at 74.81% over the last close of $3.80 |
| Recent MarketBeat actions | Morgan Stanley NYSE:MS, Needham, JPMorgan Chase & Co. NYSE:JPM, Bank of America NYSE:BAC | Targets at $5.50, $8.00, $10.00, and $6.00 | Street targets still mixed after latest updates |
Upcoming company announcements are focused on clinical or regulatory events:
| Program | Recursion timing |
|---|---|
| REC-4881, MEK1/2 | Regulatory update due in the second half of 2026; more Phase 1b/2 data expected in the first half of 2027 |
| REC-1245, RBM39 | More Phase 1 dose-escalation results expected second half 2026 |
| REC-7735 and REC-102 | Go/no-go call on starting Phase 1 will be based on data in the second half of 2026 |
| REC-617 and REC-3565 | Initial Phase 1 safety and PK readout is expected in the first half of 2027 |
| REC-4539, LSD1 | Early Phase 1 safety and PK data due second half 2027 |
Related articles: NASDAQ:RXRX
